Findings

What do systematic reviews say?

2,973 questions · 3,072 findings · 410 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 559 · 18.2%GRADE not reported 143 · 4.7%Very low 654 · 21.3%Low 833 · 27.1%Moderate 683 · 22.2%High 200 · 6.5%

Psychological therapies vs education

Cost‐effectiveness · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 222 participants
Very low

Psychological therapies and co‐intervention vs co‐intervention alone

Change in depressive symptoms · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 114 participants
Very low

Psychological therapies vs no intervention

Adverse events · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 6 participants
GRADE not reported

Psychological therapies vs no intervention

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 348 participants
Very low

Psychological therapies vs no intervention

Change in dyspnoea score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Psychological therapies vs no intervention

Lung function: FEV1 mL (change from baseline) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Psychological therapies vs no intervention

Change in exercise tolerance · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Psychological therapies vs no intervention

Change in hospital length of stay or readmission rates · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Psychological therapies vs education

Change in depressive symptoms · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 507 participants
Very low

Psychological therapies vs education

Adverse events · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Prostacyclin vs control

Improvement in WHO functional class · pulmonary arterial hypertension

Prostacyclin probably leads to higher improvement in WHO functional class compared with control (moderate certainty).

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
OR 2.39 [1.72, 3.32]
8 studies · 1066 participants
Moderate

Prostacyclin vs control

Headache+ · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 2351 participants
Moderate

Selexipag vs placebo

Improvement in WHO functional class · pulmonary arterial hypertension

Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
OR 1.61 [0.17, 15.63]
1 study · 43 participants
Moderate

Selexipag vs placebo

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
High

Selexipag vs placebo

All‐cause mortality · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
Moderate

Selexipag vs placebo

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

Headache+ · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1199 participants
High

Prostacyclin vs control

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 2283 participants
Low

Prostacyclin vs control

All‐cause mortality · pulmonary arterial hypertension

Prostacyclin probably leads to lower mortality compared with control (moderate certainty).

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
OR 0.6 [0.38, 0.94]
15 studies · 2554 participants
Moderate

Prostacyclin vs control

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1521 participants
Low